Clinical trial

PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)

Ottawa Hospital Research InstituteActive, not recruitingPhase 1Started Jan 8, 202420 enrolledCanadaNCT04754061

Abstract

The goal of this multi-centre phase I/II open-label, single-arm study is to determine the safety, feasibility, therapeutic dose, and preliminary efficacy of psilocybin microdosing to treat psychological distress among patients with advanced illness. Forty patients will receive psilocybin drug product (1-3mg per day, Mon-Fri) for 4 weeks to be administered via oral capsules by the participant. Feasibility (recruitment rate, rate of intervention and follow-up completion), safety (rate of adverse events), dosing, and preliminary efficacy (depression, anxiety, overall well-being, and global impression of change) will be measured.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepressionAnxiety

Keywords

existential distresspsychological distressmicrodosingDepression, AnxietyDistress, Emotional

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.